mRNA医薬品の世界市場（2026年～2032年）

• 英文タイトル：Global mRNA Drug Market Growth 2026-2032

• レポートコード：MR6229RQ2001 • 出版社/出版日：LP Information / 2026年9月 • レポート形態：英語、PDF、110ページ • 納品方法：Eメール（納期：3日） • 産業分類：バイオ

• 販売価格（消費税別）

Single User（1名様閲覧用）	￥570,960 (USD3,660)	▷ お問い合わせ
Multi User（10名様閲覧用）	￥856,440 (USD5,490)	▷ お問い合わせ
Corporate User（閲覧人数無制限）	￥1,141,920 (USD7,320)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

世界のmRNA医薬品市場規模は、2025年の4億3,800万米ドルから2032年には6億2,000万米ドルへと拡大すると予測されており、2026年から2032年にかけて年平均成長率（CAGR）5.2％で成長すると見込まれています。 2025年の世界のmRNA治療薬の生産能力は約2,250,000回分であり、実際の生産量は約1,750,000回分に達すると見込まれています。世界の平均市場価格は1回分あたり約320米ドルです。市場の粗利益率は主に55％から75％の範囲にある。mRNA治療薬は、メッセンジャーRNA（mRNA）分子を用いて、治療目的で特定のタンパク質を産生するよう細胞に指示を与えるバイオ医薬品の一種である。体内に送達されると、mRNA配列は細胞内に取り込まれ、細胞内の翻訳機構を利用してコード化されたタンパク質を合成する。これにより、免疫応答を誘発したり、欠損したタンパク質を補ったり、疾患に関連する生物学的経路を調節したりすることが可能となる。タンパク質や化合物を直接供給する従来の医薬品とは異なり、mRNA治療薬は、細胞が治療用タンパク質を自ら産生できるようにする遺伝的指令を提供する。これらの治療薬は通常、mRNAを保護し、細胞内への取り込みを促進するために、脂質ナノ粒子（LNP）送達システムを用いて投与される。mRNA治療薬は、ワクチン、がん免疫療法、タンパク質補充療法、および希少疾患の治療に向けて広く研究・開発が進められている。その利点には、迅速な開発サイクル、柔軟な設計、およびスケーラブルな製造プロセスが挙げられる。 mRNA治療薬産業の上流工程には、主にヌクレオシド原料、プラスミドDNAテンプレート、in vitro転写に使用される酵素、脂質ナノ粒子材料、および特殊な生化学試薬が含まれます。これらの材料は、mRNAの合成、精製、および製剤化プロセスにおいて不可欠です。中流工程には、mRNA配列の設計、in vitro転写、精製、脂質ナノ粒子を用いた封入、製剤開発、および大規模なバイオ製造が含まれます。製品の安定性と有効性を維持するためには、厳格な品質管理とコールドチェーン物流が不可欠である。下流には、製薬企業、病院、ワクチン接種プログラム、および臨床治療システムが含まれる。用途は、ワクチン、がん治療薬、感染症予防、希少疾患の治療に及ぶ。また、この業界には、受託開発・製造機関（CDMO）、臨床研究サービス、規制コンサルティングなどの支援サービスも含まれる。 mRNA治療薬市場は、mRNAベースのワクチンが世界的に成功を収めたことを受け、急速な拡大を遂げています。このプラットフォームの柔軟性と迅速な開発能力により、現代のバイオ医薬品イノベーションにおいて最も有望な技術の一つとなっています。主な成長要因の一つは、mRNA技術が感染症ワクチン以外の分野へ拡大していることです。製薬各社は、mRNAベースのがん免疫療法、タンパク質置換療法、および希少遺伝性疾患の治療法を積極的に開発しています。これらの応用分野は、mRNA治療薬の潜在的な市場範囲を大幅に広げます。もう一つの重要な要因は、送達技術、特に脂質ナノ粒子（LNP）システムの継続的な改善である。送達効率と安全性の向上により、mRNA医薬品はより幅広い組織や疾患を標的とすることが可能になっている。さらに、政府、バイオテクノロジー企業、ベンチャーキャピタルファンドからの投資増加が、研究および臨床開発を加速させている。臨床パイプラインが成熟し続けるにつれ、mRNA治療薬は将来の製薬業界においてますます重要な役割を果たすと予想される。 「mRNA医薬品業界予測」では、過去の売上高を検証し、2025年の世界のmRNA医薬品総売上高を概観するとともに、2026年から2032年までのmRNA医薬品売上高予測について、地域および市場セクター別の包括的な分析を提供しています。本レポートでは、mRNA医薬品の売上高を地域、市場セクター、サブセクター別に分類し、世界のmRNA医薬品業界について、百万米ドル単位で詳細な分析を行っています。 本インサイトレポートは、世界のmRNA医薬品市場の全体像を包括的に分析し、製品セグメンテーション、企業動向、収益、市場シェア、最新の開発動向、M&A活動に関連する主要なトレンドを浮き彫りにしています。また、本レポートでは、mRNA医薬品のポートフォリオと能力、市場参入戦略、市場での位置づけ、地理的展開に焦点を当て、世界をリードする企業の戦略を分析することで、加速する世界のmRNA医薬品市場における各企業の独自の立場をより深く理解できるようにしています。 本インサイトレポートでは、mRNA医薬品の世界的な見通しを形作る主要な市場動向、推進要因、および影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化することで、新興のビジネスチャンスを浮き彫りにしています。数百件に及ぶボトムアップ型の定性的・定量的市場データに基づく透明性の高い方法論により、本調査の予測は、世界のmRNA医薬品市場の現状と将来の軌跡について、極めて精緻な見解を提供します。 本レポートでは、製品タイプ、用途、主要メーカー、および主要地域・国別に、mRNA医薬品市場の包括的な概要、市場シェア、成長機会を提示しています。 タイプ別セグメンテーション： 予防用ワクチン（感染症） 治療用ワクチン（がん） 標的細胞別のセグメンテーション： 筋肉内（樹状細胞）mRNA 静脈内（肝臓標的）mRNA 皮内（皮膚APC）mRNA 吸入（肺上皮）mRNA 製造規模別セグメンテーション： 実験室規模（前臨床、1g未満） パイロット規模（第I/II相、1～100g） 商業規模（第III相／市販、100g超） 用途別セグメンテーション： 製薬会社 医療機関 その他 本レポートでは、地域別にも市場を分類しています： 南北アメリカ 米国 カナダ メキシコ ブラジル アジア太平洋地域（APAC） 中国 日本 韓国 東南アジア インド オーストラリア 欧州 ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下に紹介する企業は、主要な専門家からの情報および各社の事業範囲、製品ポートフォリオ、市場浸透度を分析した上で選定されています。 Moderna Pfizer Zydus Cadila Fosun Pharma CureVAC BioNtech AstraZeneca Janssen

The global mRNA Drug market size is predicted to grow from US$ 438 million in 2025 to US$ 620 million in 2032; it is expected to grow at a CAGR of 5.2% from 2026 to 2032.

In 2025, global mRNA therapeutics production capacity is about 2,250,000 doses, with actual production reaching approximately 1,750,000 doses. The average global market price is around US$ 320 per dose. The market gross margin mainly ranges between 55% and 75%. mRNA therapeutics are a class of biopharmaceutical products that use messenger RNA (mRNA) molecules to instruct cells to produce specific proteins for therapeutic purposes. After delivery into the body, the mRNA sequence enters cells and utilizes the cellular translation machinery to synthesize the encoded protein, which can trigger immune responses, replace missing proteins, or modulate disease-related biological pathways. Unlike traditional drugs that directly supply proteins or chemical compounds, mRNA therapeutics provide genetic instructions that enable cells to produce the therapeutic proteins themselves. These therapies are typically delivered using lipid nanoparticle (LNP) delivery systems to protect the mRNA and facilitate cellular uptake. mRNA therapeutics have been widely studied and developed for vaccines, cancer immunotherapy, protein replacement therapy, and rare disease treatment. Their advantages include rapid development cycles, flexible design, and scalable manufacturing processes.

The upstream of the mRNA therapeutics industry mainly includes nucleoside raw materials, plasmid DNA templates, enzymes used in in vitro transcription, lipid nanoparticle materials, and specialized biochemical reagents. These materials are critical for mRNA synthesis, purification, and formulation processes. The midstream involves mRNA sequence design, in vitro transcription, purification, encapsulation using lipid nanoparticles, formulation development, and large-scale biomanufacturing. Strict quality control and cold-chain logistics are essential to maintain product stability and efficacy. The downstream includes pharmaceutical companies, hospitals, vaccination programs, and clinical treatment systems. Applications span vaccines, oncology therapeutics, infectious disease prevention, and rare disease treatment. The industry also includes supporting services such as contract development and manufacturing organizations (CDMOs), clinical research services, and regulatory consulting.

The mRNA therapeutics market has experienced rapid expansion following the global success of mRNA-based vaccines. The platform’s flexibility and rapid development capability have made it one of the most promising technologies in modern biopharmaceutical innovation. One of the primary growth drivers is the expansion of mRNA technology beyond infectious disease vaccines. Pharmaceutical companies are actively developing mRNA-based cancer immunotherapies, protein replacement therapies, and treatments for rare genetic diseases. These applications significantly broaden the potential market scope of mRNA therapeutics. Another important factor is the continuous improvement of delivery technologies, particularly lipid nanoparticle (LNP) systems. Advances in delivery efficiency and safety are enabling mRNA drugs to target a wider range of tissues and diseases. In addition, increasing investments from governments, biotechnology companies, and venture capital funds are accelerating research and clinical development. As clinical pipelines continue to mature, mRNA therapeutics are expected to play an increasingly important role in the future pharmaceutical landscape.

The “mRNA Drug Industry Forecast” looks at past sales and reviews total world mRNA Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected mRNA Drug sales for 2026 through 2032. With mRNA Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Drug industry.

This Insight Report provides a comprehensive analysis of the global mRNA Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global mRNA Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Prophylactic Vaccine (Infectious Disease)
Therapeutic Vaccine (Cancer)

Segmentation by Target Cell:
Intramuscular (Dendritic Cell) mRNA
Intravenous (Liver-targeted) mRNA
Intradermal (Skin APC) mRNA
Inhalation (Lung epithelial) mRNA

Segmentation by Manufacturing Scale:
Lab-scale (Preclinical, <1g) Pilot-scale (Phase I/II, 1-100g) Commercial-scale (Phase III/Market, >100g)

Segmentation by Application:
Pharmaceutical Companies
Medical Institutions
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company’s coverage, product portfolio, its market penetration.

Moderna
Pfizer
Zydus Cadila
Fosun Pharma
CureVAC
BioNtech
AstraZeneca
Janssen

レポート目次

---

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global mRNA Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for mRNA Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for mRNA Drug by Country/Region, 2021, 2025 & 2032
2.2 mRNA Drug Segment by Type
2.2.1 Prophylactic Vaccine (Infectious Disease)
2.2.2 Therapeutic Vaccine (Cancer)
2.2.3 mRNA Drug Sales by Type
2.2.3.1 Global mRNA Drug Sales Market Share by Type (2021-2026)
2.2.3.2 Global mRNA Drug Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global mRNA Drug Sale Price by Type (2021-2026)
2.3 mRNA Drug Segment by Target Cell
2.3.1 Intramuscular (Dendritic Cell) mRNA
2.3.2 Intravenous (Liver-targeted) mRNA
2.3.3 Intradermal (Skin APC) mRNA
2.3.4 Inhalation (Lung epithelial) mRNA
2.3.5 mRNA Drug Sales by Target Cell
2.3.5.1 Global mRNA Drug Sales Market Share by Target Cell (2021-2026)
2.3.5.2 Global mRNA Drug Revenue and Market Share by Target Cell (2021-2026)
2.3.5.3 Global mRNA Drug Sale Price by Target Cell (2021-2026)
2.4 mRNA Drug Segment by Manufacturing Scale
2.4.1 Lab-scale (Preclinical, <1g) 2.4.2 Pilot-scale (Phase I/II, 1-100g) 2.4.3 Commercial-scale (Phase III/Market, >100g)
2.4.4 mRNA Drug Sales by Manufacturing Scale
2.4.4.1 Global mRNA Drug Sales Market Share by Manufacturing Scale (2021-2026)
2.4.4.2 Global mRNA Drug Revenue and Market Share by Manufacturing Scale (2021-2026)
2.4.4.3 Global mRNA Drug Sale Price by Manufacturing Scale (2021-2026)
2.5 mRNA Drug Segment by Application
2.5.1 Pharmaceutical Companies
2.5.2 Medical Institutions
2.5.3 Others
2.5.4 mRNA Drug Sales by Application
2.5.4.1 Global mRNA Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global mRNA Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global mRNA Drug Sale Price by Application (2021-2026)
3 Global by Company
3.1 Global mRNA Drug Breakdown Data by Company
3.1.1 Global mRNA Drug Annual Sales by Company (2021-2026)
3.1.2 Global mRNA Drug Sales Market Share by Company (2021-2026)
3.2 Global mRNA Drug Annual Revenue by Company (2021-2026)
3.2.1 Global mRNA Drug Revenue by Company (2021-2026)
3.2.2 Global mRNA Drug Revenue Market Share by Company (2021-2026)
3.3 Global mRNA Drug Sale Price by Company
3.4 Key Manufacturers mRNA Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers mRNA Drug Product Location Distribution
3.4.2 Players mRNA Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for mRNA Drug by Geographic Region
4.1 World Historic mRNA Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global mRNA Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global mRNA Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic mRNA Drug Market Size by Country/Region (2021-2026)
4.2.1 Global mRNA Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global mRNA Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas mRNA Drug Sales Growth
4.4 APAC mRNA Drug Sales Growth
4.5 Europe mRNA Drug Sales Growth
4.6 Middle East & Africa mRNA Drug Sales Growth
5 Americas
5.1 Americas mRNA Drug Sales by Country
5.1.1 Americas mRNA Drug Sales by Country (2021-2026)
5.1.2 Americas mRNA Drug Revenue by Country (2021-2026)
5.2 Americas mRNA Drug Sales by Type (2021-2026)
5.3 Americas mRNA Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Drug Sales by Region
6.1.1 APAC mRNA Drug Sales by Region (2021-2026)
6.1.2 APAC mRNA Drug Revenue by Region (2021-2026)
6.2 APAC mRNA Drug Sales by Type (2021-2026)
6.3 APAC mRNA Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe mRNA Drug by Country
7.1.1 Europe mRNA Drug Sales by Country (2021-2026)
7.1.2 Europe mRNA Drug Revenue by Country (2021-2026)
7.2 Europe mRNA Drug Sales by Type (2021-2026)
7.3 Europe mRNA Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa mRNA Drug by Country
8.1.1 Middle East & Africa mRNA Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa mRNA Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa mRNA Drug Sales by Type (2021-2026)
8.3 Middle East & Africa mRNA Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of mRNA Drug
10.3 Manufacturing Process Analysis of mRNA Drug
10.4 Industry Chain Structure of mRNA Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 mRNA Drug Distributors
11.3 mRNA Drug Customer
12 World Forecast Review for mRNA Drug by Geographic Region
12.1 Global mRNA Drug Market Size Forecast by Region
12.1.1 Global mRNA Drug Forecast by Region (2027-2032)
12.1.2 Global mRNA Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global mRNA Drug Forecast by Type (2027-2032)
12.7 Global mRNA Drug Forecast by Application (2027-2032)
13 Key Players Analysis
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna mRNA Drug Product Portfolios and Specifications
13.1.3 Moderna mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer mRNA Drug Product Portfolios and Specifications
13.2.3 Pfizer mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Zydus Cadila
13.3.1 Zydus Cadila Company Information
13.3.2 Zydus Cadila mRNA Drug Product Portfolios and Specifications
13.3.3 Zydus Cadila mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Zydus Cadila Main Business Overview
13.3.5 Zydus Cadila Latest Developments
13.4 Fosun Pharma
13.4.1 Fosun Pharma Company Information
13.4.2 Fosun Pharma mRNA Drug Product Portfolios and Specifications
13.4.3 Fosun Pharma mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Fosun Pharma Main Business Overview
13.4.5 Fosun Pharma Latest Developments
13.5 CureVAC
13.5.1 CureVAC Company Information
13.5.2 CureVAC mRNA Drug Product Portfolios and Specifications
13.5.3 CureVAC mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 CureVAC Main Business Overview
13.5.5 CureVAC Latest Developments
13.6 BioNtech
13.6.1 BioNtech Company Information
13.6.2 BioNtech mRNA Drug Product Portfolios and Specifications
13.6.3 BioNtech mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 BioNtech Main Business Overview
13.6.5 BioNtech Latest Developments
13.7 AstraZeneca
13.7.1 AstraZeneca Company Information
13.7.2 AstraZeneca mRNA Drug Product Portfolios and Specifications
13.7.3 AstraZeneca mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 AstraZeneca Main Business Overview
13.7.5 AstraZeneca Latest Developments
13.8 Janssen
13.8.1 Janssen Company Information
13.8.2 Janssen mRNA Drug Product Portfolios and Specifications
13.8.3 Janssen mRNA Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Janssen Main Business Overview
13.8.5 Janssen Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. mRNA Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. mRNA Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Prophylactic Vaccine (Infectious Disease)
Table 4. Major Players of Therapeutic Vaccine (Cancer)
Table 5. Global mRNA Drug Sales by Type (2021-2026) & (K Dose)
Table 6. Global mRNA Drug Sales Market Share by Type (2021-2026)
Table 7. Global mRNA Drug Revenue by Type (2021-2026) & ($ million)
Table 8. Global mRNA Drug Revenue Market Share by Type (2021-2026)
Table 9. Global mRNA Drug Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Intramuscular (Dendritic Cell) mRNA
Table 11. Major Players of Intravenous (Liver-targeted) mRNA
Table 12. Major Players of Intradermal (Skin APC) mRNA
Table 13. Major Players of Inhalation (Lung epithelial) mRNA
Table 14. Global mRNA Drug Sales by Target Cell (2021-2026) & (K Dose)
Table 15. Global mRNA Drug Sales Market Share by Target Cell (2021-2026)
Table 16. Global mRNA Drug Revenue by Target Cell (2021-2026) & ($ million)
Table 17. Global mRNA Drug Revenue Market Share by Target Cell (2021-2026)
Table 18. Global mRNA Drug Sale Price by Target Cell (2021-2026) & (US$/Dose)
Table 19. Major Players of Lab-scale (Preclinical, <1g) Table 20. Major Players of Pilot-scale (Phase I/II, 1-100g) Table 21. Major Players of Commercial-scale (Phase III/Market, >100g)
Table 22. Global mRNA Drug Sales by Manufacturing Scale (2021-2026) & (K Dose)
Table 23. Global mRNA Drug Sales Market Share by Manufacturing Scale (2021-2026)
Table 24. Global mRNA Drug Revenue by Manufacturing Scale (2021-2026) & ($ million)
Table 25. Global mRNA Drug Revenue Market Share by Manufacturing Scale (2021-2026)
Table 26. Global mRNA Drug Sale Price by Manufacturing Scale (2021-2026) & (US$/Dose)
Table 27. Global mRNA Drug Sale by Application (2021-2026) & (K Dose)
Table 28. Global mRNA Drug Sale Market Share by Application (2021-2026)
Table 29. Global mRNA Drug Revenue by Application (2021-2026) & ($ million)
Table 30. Global mRNA Drug Revenue Market Share by Application (2021-2026)
Table 31. Global mRNA Drug Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global mRNA Drug Sales by Company (2021-2026) & (K Dose)
Table 33. Global mRNA Drug Sales Market Share by Company (2021-2026)
Table 34. Global mRNA Drug Revenue by Company (2021-2026) & ($ millions)
Table 35. Global mRNA Drug Revenue Market Share by Company (2021-2026)
Table 36. Global mRNA Drug Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers mRNA Drug Producing Area Distribution and Sales Area
Table 38. Players mRNA Drug Products Offered
Table 39. mRNA Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global mRNA Drug Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global mRNA Drug Sales Market Share Geographic Region (2021-2026)
Table 44. Global mRNA Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global mRNA Drug Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global mRNA Drug Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global mRNA Drug Sales Market Share by Country/Region (2021-2026)
Table 48. Global mRNA Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global mRNA Drug Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas mRNA Drug Sales by Country (2021-2026) & (K Dose)
Table 51. Americas mRNA Drug Sales Market Share by Country (2021-2026)
Table 52. Americas mRNA Drug Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas mRNA Drug Sales by Type (2021-2026) & (K Dose)
Table 54. Americas mRNA Drug Sales by Application (2021-2026) & (K Dose)
Table 55. APAC mRNA Drug Sales by Region (2021-2026) & (K Dose)
Table 56. APAC mRNA Drug Sales Market Share by Region (2021-2026)
Table 57. APAC mRNA Drug Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC mRNA Drug Sales by Type (2021-2026) & (K Dose)
Table 59. APAC mRNA Drug Sales by Application (2021-2026) & (K Dose)
Table 60. Europe mRNA Drug Sales by Country (2021-2026) & (K Dose)
Table 61. Europe mRNA Drug Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe mRNA Drug Sales by Type (2021-2026) & (K Dose)
Table 63. Europe mRNA Drug Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa mRNA Drug Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa mRNA Drug Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa mRNA Drug Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa mRNA Drug Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of mRNA Drug
Table 69. Key Market Challenges & Risks of mRNA Drug
Table 70. Key Industry Trends of mRNA Drug
Table 71. mRNA Drug Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. mRNA Drug Distributors List
Table 74. mRNA Drug Customer List
Table 75. Global mRNA Drug Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global mRNA Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas mRNA Drug Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas mRNA Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC mRNA Drug Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC mRNA Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe mRNA Drug Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe mRNA Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa mRNA Drug Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa mRNA Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global mRNA Drug Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global mRNA Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global mRNA Drug Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global mRNA Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Moderna Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Moderna mRNA Drug Product Portfolios and Specifications
Table 91. Moderna mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Moderna Main Business
Table 93. Moderna Latest Developments
Table 94. Pfizer Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer mRNA Drug Product Portfolios and Specifications
Table 96. Pfizer mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Zydus Cadila Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Zydus Cadila mRNA Drug Product Portfolios and Specifications
Table 101. Zydus Cadila mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Zydus Cadila Main Business
Table 103. Zydus Cadila Latest Developments
Table 104. Fosun Pharma Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Fosun Pharma mRNA Drug Product Portfolios and Specifications
Table 106. Fosun Pharma mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Fosun Pharma Main Business
Table 108. Fosun Pharma Latest Developments
Table 109. CureVAC Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. CureVAC mRNA Drug Product Portfolios and Specifications
Table 111. CureVAC mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. CureVAC Main Business
Table 113. CureVAC Latest Developments
Table 114. BioNtech Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. BioNtech mRNA Drug Product Portfolios and Specifications
Table 116. BioNtech mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. BioNtech Main Business
Table 118. BioNtech Latest Developments
Table 119. AstraZeneca Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. AstraZeneca mRNA Drug Product Portfolios and Specifications
Table 121. AstraZeneca mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. AstraZeneca Main Business
Table 123. AstraZeneca Latest Developments
Table 124. Janssen Basic Information, mRNA Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Janssen mRNA Drug Product Portfolios and Specifications
Table 126. Janssen mRNA Drug Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Janssen Main Business
Table 128. Janssen Latest Developments

---